Skip to main content
. 2016 Feb 16;213(12):1996–2004. doi: 10.1093/infdis/jiw066

Table 2.

Effects of Maternal Helminth Infections on Vaccine Antibody Titers

Antigen Fold Change (95% CI) P Values
Adjusted Fold Change (95% CI) P Values
2-Sided Adjusted for Helminth Detection in Child at Age 13 mo Corrected by Holm Method Adjusted Adjusted for Helminth Detection in Child at Age 13 mo Corrected by Holm Method
Primary end point
 Rotavirus 1.31 (1.14–1.5) .0002 .0041 .0003 1.21 (1.05–1.4) .0104 .0505 .0147
 OPV1 1.25 (1.12–1.4) .0001 .0045 .0002 1.18 (1.06–1.33) .0036 .1667 .0108
 OPV3 1.19 (1.08–1.31) .0003 .1577 .0003 1.15 (1.04–1.27) .0073 .7717 .0147
Secondary end point
 Diphtheria toxoid 0.88 (.77–1) .0527 .1215 .2108 0.87 (.76–1) .0447 .2510 .2679
 Tetanus toxoid 0.87 (.77–.99) .0298 .0040 .1489 0.90 (.79–1.03) .1158 .0028 .5792
B. pertussis 0.9 (.75–1.08) .2755 .0015 .8264 1.05 (.86–1.27) .6440 .0036 1.0000
 Measles virus 0.72 (.58–.88) .0015 .3800 .0092 0.99 (.82–1.18) .8756 .6585 1.0000
 Rubella virus 0.96 (.87–1.05) .3689 .5774 .8264 1.04 (.96–1.14) .3280 .5786 1.0000
 Hib 0.91 (.77–1.08) .2865 .0483 .8264 0.92 (.77–1.09) .3346 .0198 1.0000

Table shows fold changes representing ratios of geometric mean antibody titers for infants of infected mothers, compared with uninfected mothers. A generalized additive model was adjusted for calendar time, sex, child's age, helminth infection status at the 13-month evaluation, socioeconomic status, mother's antiparasite treatment, mother's education level, mother's ethnicity, urban versus rural residence, and overcrowding of home. In addition, for the tetanus toxoid response only, adjustments were made for the number of doses of tetanus toxoid received by the mother during pregnancy. The Holm method was used to adjust for multiple comparisons separately for primary and secondary end points.

Abbreviations: B. pertussis, Bordetella pertussis; CI, confidence interval; Hib, Haemophilus influenzae b; OPV1, poliovirus serotype 1 component of oral polio vaccine; OPV3, poliovirus serotype 3 component of oral polio vaccine.